Effects of olanzapine on  31 P MRS metabolic markers in schizophrenia | Zendy

Nenadic Igor | Zendy; Dietzek Maren | Zendy; Langbein Kerstin | Zendy; Rzanny Reinhard | Zendy; Gussew Alexander | Zendy; Reichenbach Jürgen R. | Zendy; Sauer Heinrich | Zendy; Smesny Stefan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Effects of olanzapine on 31 P MRS metabolic markers in schizophrenia

Author(s) -

Nenadic Igor,

Dietzek Maren,

Langbein Kerstin,

Rzanny Reinhard,

Gussew Alexander,

Reichenbach Jürgen R.,

Sauer Heinrich,

Smesny Stefan

Publication year - 2013

Publication title -

human psychopharmacology: clinical and experimental

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.461

H-Index - 78

eISSN - 1099-1077

pISSN - 0885-6222

DOI - 10.1002/hup.2274

Subject(s) - olanzapine , schizophrenia (object oriented programming) , antipsychotic , medicine , endocrinology , adenosine triphosphate , cerebellum , phosphocreatine , energy metabolism , chemistry , pharmacology , psychiatry

Antipsychotic drug action might include mechanisms related to normalising phospholipid and high‐energy metabolism. We applied brain metabolic imaging with 31 P magnetic resonance spectroscopy ( 31 P MRS) and two‐dimensional chemical shift imaging to assess changes of metabolism of phospholipids and high‐energy phosphates in schizophrenia patients at baseline (four antipsychotic‐naïve and three off antipsychotics) and at follow‐up, after 6 weeks of treatment with olanzapine. Results indicate a significant increase of adenosine‐triphosphate (ATP) in the right inferior temporal cortex and a trend towards ATP decrease in the left cerebellum. This suggests a shift in high‐energy phosphates (rather than phospholipids), possibly related to normalisation of functioning in these areas. Copyright © 2012 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research